Overview

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that a new formulation of an Bendamustine (BDM) Hydrochloride (HCl) is bioequivalent (BE) (similar) to the commercially available product in patients with cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Eagle Pharmaceuticals, Inc.

Treatments:

Bendamustine Hydrochloride